Grace Therapeutics (GRCE) holder lifts indirect stake to 2.76M shares

Rhea-AI Filing Summary

Grace Therapeutics, Inc. (GRCE) had a Form 4 filed for Opaleye Management Inc., a more-than-ten-percent holder, reporting an open-market purchase of 11,608 shares of common stock on August 14, 2026 at a weighted average price of $2.0853 per share. The shares are held indirectly by Opaleye, L.P., with Opaleye Management Inc. potentially deemed a beneficial owner through its role as investment manager but disclaiming beneficial ownership except to the extent of its pecuniary interest. Following this transaction, 2,760,000 shares are reported as held indirectly by Opaleye, L.P.

Insider Trade Summary

Net Buyer: 11,608 shares

Net Buy 1 txn

Insider Opaleye Management Inc.

Role 10% Owner

Bought 11,608 shs ($24K)

Type	Security	Shares	Price	Value
Purchase	Common Stock, par value $0.0001 per share F2, F1, F3	11,608	$2.0853	$24K

Holdings After Transaction: Common Stock, par value $0.0001 per share — 2,760,000 shares (Indirect, By Opaleye, L.P.)

Footnotes (3)

1. F1. Represents securities owned directly by Opaleye, L.P. (the "Fund"). As the investment manager of the Fund, Opaleye Management, Inc. may be deemed to beneficially own the securities owned directly by the Fund.
2. F2. The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.05 to $2.09. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each separate price within the range.
3. F3. Opaleye Management, Inc. disclaims beneficial ownership of the shares reported herein except to the extent of its pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that Opaleye Management, Inc. is the beneficial owner of any such shares for purposes of Section 16(a) of the Securities Exchange Act of 1934, as amended, or for any other purpose.

Key Figures

Shares purchased: 11,608 shares Weighted average purchase price: $2.0853 per share Price range of purchases: $2.05 to $2.09 per share +1 more

4 metrics

Shares purchased 11,608 shares Common Stock acquired on August 14, 2026 in open-market transactions

Weighted average purchase price $2.0853 per share Average price across multiple purchase trades between $2.05 and $2.09

Price range of purchases $2.05 to $2.09 per share Range of transaction prices for the August 14, 2026 purchases

Shares held after transaction 2,760,000 shares Total indirect holdings reported for Opaleye, L.P. after the purchase

Key Terms

weighted average price, beneficially own, pecuniary interest

3 terms

weighted average price financial

"The price reported is a weighted average price."

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

beneficially own financial

"may be deemed to beneficially own the securities owned directly by the Fund"

Beneficially own means having the economic rights and risks of a security—such as the right to receive dividends, sell the shares, or profit from price changes—whether or not your name appears on the official share register. Think of it like renting a car: you use it and reap the benefits even if the title lists someone else. Investors care because beneficial ownership determines who truly controls value, must be disclosed under securities rules, and can signal potential influence or trading activity that affects a stock’s price.

pecuniary interest financial

"disclaims beneficial ownership of the shares reported herein except to the extent of its pecuniary interest"

FAQ

What insider transaction did GRCE disclose for Opaleye Management Inc. on this Form 4?

The filing reports that an entity associated with Opaleye Management Inc. purchased 11,608 shares of Grace Therapeutics common stock on August 14, 2026. These shares were acquired in an open-market transaction and are held indirectly through Opaleye, L.P. as noted in the ownership footnotes.

At what price were the GRCE shares purchased in the reported Form 4 transaction?

The reported transaction used a weighted average price of $2.0853 per share. Footnotes explain the shares were bought in multiple trades, with individual prices ranging from $2.05 to $2.09, and full trade details are available upon request to the appropriate parties.

How many GRCE shares does the reporting holder show after this Form 4 transaction?

After the reported purchase, the Form 4 shows 2,760,000 shares of Grace Therapeutics common stock held indirectly. These shares are owned directly by Opaleye, L.P., while Opaleye Management Inc. is the investment manager and may be deemed a beneficial owner, subject to its stated disclaimer.

Who actually holds the GRCE shares referenced in Opaleye Management Inc.’s Form 4?

The shares are held directly by Opaleye, L.P., described as the Fund. Opaleye Management Inc. serves as the Fund’s investment manager and may be deemed to beneficially own the securities, but it disclaims beneficial ownership except to the extent of its pecuniary interest in them.

Was the GRCE insider purchase by Opaleye Management Inc. made under a Rule 10b5-1 trading plan?

The Form 4 indicates the Rule 10b5-1 checkbox is not marked as affirmative, and no footnote states that the transaction was executed under a Rule 10b5-1 trading plan, so the filing does not characterize it as a pre-arranged plan trade.

What does Opaleye Management Inc. disclose about beneficial ownership of the GRCE shares?

Opaleye Management Inc. states it disclaims beneficial ownership of the reported shares except to the extent of its pecuniary interest. The filing notes that, as investment manager of Opaleye, L.P., it may be deemed to beneficially own the Fund’s shares but does not concede such ownership.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 08/19/2026 - 07:45 AM Accepted by SEC EDGAR 08/19/2026 - 07:44 AM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Opaleye Management Inc.

(Last) (First) (Middle)

ONE BOSTON PLACE, 26TH FLOOR

(Street)

BOSTON MASSACHUSETTS 02108

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Grace Therapeutics, Inc. [ GRCE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/14/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock, par value $0.0001 per share	08/14/2026		P		11,608	A	$2.0853(2)	2,760,000	I	By Opaleye, L.P.(1)(3)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents securities owned directly by Opaleye, L.P. (the "Fund"). As the investment manager of the Fund, Opaleye Management, Inc. may be deemed to beneficially own the securities owned directly by the Fund.

2. The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.05 to $2.09. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each separate price within the range.

3. Opaleye Management, Inc. disclaims beneficial ownership of the shares reported herein except to the extent of its pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that Opaleye Management, Inc. is the beneficial owner of any such shares for purposes of Section 16(a) of the Securities Exchange Act of 1934, as amended, or for any other purpose.

	Opaleye Management, Inc., By: /s/ James Silverman, President	08/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)